MuhHwan Su - SynCore Biotechnology General Manager
| 4192 Stock | TWD 35.25 0.40 1.15% |
Executive
Mr. MuhHwan Su was serving as General Manager in SynCore Biotechnology Co., Ltd. since June 15, 2018. He holds a Ph.D. in Pharmacy from University of Utah, the United States. He is also an Adjunct Associate Professor of National Defense Medical Center, Taiwan. since 2018.
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 886 3 958 6101 |
| Web | https://www.syncorebio.com |
SynCore Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4348) %, meaning that it generated substantial loss on money invested by shareholders. SynCore Biotechnology's management efficiency ratios could be used to measure how well SynCore Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | EXECUTIVE Age | ||
| Amy Huang | OBI Pharma | N/A | |
| Jose Hsieh | PharmaEngine | N/A | |
| JiannShiun Lai | OBI Pharma | N/A | |
| ChengDer Yu | OBI Pharma | N/A | |
| Yuping Yang | Medigen Vaccine Biologics | N/A | |
| Fei Pan | Adimmune Corp | N/A | |
| Sophia Lee | OBI Pharma | N/A | |
Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.16 |
SynCore Biotechnology Leadership Team
Elected by the shareholders, the SynCore Biotechnology's board of directors comprises two types of representatives: SynCore Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SynCore. The board's role is to monitor SynCore Biotechnology's management team and ensure that shareholders' interests are well served. SynCore Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SynCore Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChiaHao Liang, Senior Manager of Finance & Accounting | ||
| MuhHwan Su, General Manager | ||
| WenHsin Huang, VP Department | ||
| FernFang Lin, VP Devel | ||
| ChihWen Lee, Chairman of the Board | ||
| CharnJung Chang, General Manager-Ophthalmology Project | ||
| HuiHung MBA, VP Drugs | ||
| RueyWen Lin, Head Department |
SynCore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SynCore Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (13.97) % | |||
| Current Valuation | 2.86 B | |||
| Shares Outstanding | 115.08 M | |||
| Shares Owned By Insiders | 66.92 % | |||
| Price To Book | 9.34 X | |||
| Price To Sales | 221.58 X | |||
| Revenue | 6.94 M | |||
| Gross Profit | 2.97 M |
Pair Trading with SynCore Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SynCore Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SynCore Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with SynCore Stock
| 0.87 | 4743 | Oneness Biotech | PairCorr |
| 0.88 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.83 | 4174 | OBI Pharma | PairCorr |
Moving against SynCore Stock
| 0.87 | 2891 | CTBC Financial Holding | PairCorr |
| 0.87 | 2891B | CTBC Financial Holding | PairCorr |
| 0.81 | 2883 | China Development | PairCorr |
| 0.66 | 2330 | Taiwan Semiconductor | PairCorr |
| 0.66 | 0050 | YuantaP shares Taiwan | PairCorr |
The ability to find closely correlated positions to SynCore Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SynCore Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SynCore Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SynCore Biotechnology Co to buy it.
The correlation of SynCore Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SynCore Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SynCore Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SynCore Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.